Trilexium

Overview

Trilexium (TRX-E-009-1) is a third-generation of benzopyran structurally related to TRX-E-002-1 ( HY-114250 ). Trilexium increases p21 protein expression and induces apoptosis . Trilexium depolymerizes microtubules . Trilexium shows broad anti-cancer activity.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Microtubule/Tubulin | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-157800
• CAS No.: 1983180-82-0
• Molecular Formula: C24H23FO6
• Molecular Weight: 426.43
• Purity: 99.70%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 5 mg/mL (11.73 mM); Clear solution
• Availability: In-stock

Source

Original product source